| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Multiple targets: antitumor, antioxidant, antimicrobial, antiviral pathways.
|
|---|---|
| ln Vitro |
Kuwanon O exhibits antitumor activity, making it of interest for cancer research. It has antioxidant properties, which contribute to its potential protective effects against oxidative stress. The compound also shows anti-radiation, anti-mutation, antibacterial, and antiviral activities. It enhances immune function. As a flavonoid derivative, it is expected to interact with various cellular targets involved in inflammation, oxidative stress, and cell proliferation.
|
| ln Vivo |
In vivo studies of Kuwanon O are limited, but its reported biological activities (antitumor, antioxidant, antimicrobial, antiviral, immune-enhancing) suggest potential therapeutic applications. As a natural product from mulberry root bark, it may contribute to the traditional medicinal uses of Morus species. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic properties.
|
| Enzyme Assay |
Standard assays for evaluating Kuwanon O's activities include: antitumor assays using cancer cell lines (MTT, colony formation, apoptosis assays); antioxidant assays (DPPH radical scavenging, ABTS, FRAP); antimicrobial assays (broth microdilution for MIC determination against bacterial and fungal strains); antiviral assays (plaque reduction or cytopathic effect inhibition assays); and immune-enhancing assays (measuring cytokine production, lymphocyte proliferation). For enzyme inhibition studies, specific target enzymes are incubated with the compound and activity is measured spectrophotometrically.
|
| Cell Assay |
Cell-based assays for Kuwanon O use various cancer cell lines for antitumor studies. Cells are treated with the compound at different concentrations and cell viability is measured by MTT or similar assays. Apoptosis is assessed by flow cytometry using Annexin V/PI staining. For antioxidant studies, cells are exposed to oxidative stress inducers and protective effects are evaluated. For antimicrobial studies, bacterial or fungal cultures are treated with the compound and growth inhibition is measured. For antiviral studies, virus-infected cells are treated and viral replication is assessed.
|
| Animal Protocol |
In vivo animal studies for Kuwanon O are limited in the published literature. Based on its reported activities, potential animal models include: tumor xenograft models for antitumor evaluation; inflammation models (e.g., carrageenan-induced paw edema) for anti-inflammatory assessment; and infection models for antimicrobial/antiviral evaluation. Standard protocols for these models would involve administration of the compound (oral, intraperitoneal, or intravenous) followed by measurement of relevant endpoints.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic data for Kuwanon O are limited. As a flavonoid derivative with a molecular weight of 694.72 g/mol, it is expected to have moderate oral bioavailability. The compound is soluble in methanol, ethanol, DMSO, and other organic solvents. It should be stored as a powder at 2-8°C. Purity is typically ≥95%. The compound is used as a reference standard for content determination and scientific research.
|
| Toxicity/Toxicokinetics |
Toxicological data for Kuwanon O are limited. As a natural flavonoid derivative, it is generally considered to have low toxicity. However, comprehensive toxicity studies have not been reported. The compound exhibits antimicrobial and antiviral activities, indicating biological activity at certain concentrations. Standard laboratory safety practices should be followed when handling this compound. It is intended for research use only.
|
| References | |
| Additional Infomation |
It has been reported that Morus lhou and Morus alba contain Kuwanon O, and there is relevant data.
Kuwanon O is a natural flavonoid derivative from the root bark of Morus lhou (set.) Koidz (mulberry). Mulberry root bark has been used in traditional medicine, and Kuwanon O is one of the bioactive constituents contributing to its pharmacological effects. The compound's multiple biological activities (antitumor, antioxidant, anti-radiation, anti-mutation, antibacterial, antiviral, immune-enhancing) make it a compound of interest for drug discovery and development. It is used primarily as a reference standard and for research purposes. |
| Molecular Formula |
C40H38O11
|
|---|---|
| Molecular Weight |
694.72312
|
| Exact Mass |
694.241
|
| CAS # |
89200-01-1
|
| PubChem CID |
102075992
|
| Appearance |
Light yellow to yellow solid
|
| LogP |
7
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
51
|
| Complexity |
1310
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC1=C[C@@H]([C@H]([C@@H](C1)C2=C(C=C(C=C2)O)O)C(=O)C3=C(C(=C(C=C3)O)CC=C(C)C)O)C4=C(C=CC(=C4O)[C@@H]5CC(=O)C6=C(C=C(C=C6O5)O)O)O
|
| InChi Key |
YIHMXHFAOIEYBW-BHNQILPDSA-N
|
| InChi Code |
InChI=1S/C40H38O11/c1-18(2)4-6-23-28(43)10-9-25(38(23)48)40(50)35-26(22-7-5-20(41)14-30(22)45)12-19(3)13-27(35)36-29(44)11-8-24(39(36)49)33-17-32(47)37-31(46)15-21(42)16-34(37)51-33/h4-5,7-11,13-16,26-27,33,35,41-46,48-49H,6,12,17H2,1-3H3/t26-,27-,33-,35-/m0/s1
|
| Chemical Name |
(2S)-2-[3-[(1S,5R,6S)-6-[2,4-dihydroxy-3-(3-methylbut-2-enyl)benzoyl]-5-(2,4-dihydroxyphenyl)-3-methylcyclohex-2-en-1-yl]-2,4-dihydroxyphenyl]-5,7-dihydroxy-2,3-dihydrochromen-4-one
|
| Synonyms |
Kuwanon O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4394 mL | 7.1971 mL | 14.3943 mL | |
| 5 mM | 0.2879 mL | 1.4394 mL | 2.8789 mL | |
| 10 mM | 0.1439 mL | 0.7197 mL | 1.4394 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
